Clinical Scorecard: Microbiological and Clinical Features of Polymicrobial Bloodstream Infections in Patients with Hematologic Malignancies: A Cross-Sectional Analysis

At a Glance

Key Highlights

• PBSIs account for 19.4% of bloodstream infections in hematologic patients
• Infection-related mortality rates can reach up to 40%
• Common pathogens include gram-positive cocci and multidrug-resistant gram-negative bacteria
• Prompt empirical antibiotic therapy is crucial for reducing morbidity and mortality
• Hospital stays longer than 30 days observed in 52.4% of PBSI patients

Guideline-Based Recommendations

Diagnosis

• Bloodstream infection defined by isolation of pathogens in blood cultures
• PBSI defined as isolation of two or more bacterial species from blood cultures

Management

• Initiate empirical antibiotic treatment upon fever onset
• Adjust treatment based on pathogen identification and susceptibility

Monitoring & Follow-up

• Assess infection-related mortality within 30 days of infection onset
• Monitor for signs of sepsis and septic shock

Risks

• High mortality risk associated with PBSIs in immunocompromised patients
• Increased resistance rates complicate treatment

Patient & Prescribing Data

Patients with hematologic malignancies undergoing chemotherapy

42.9% of PBSI patients received steroid treatment

Clinical Best Practices

• Consider resistance patterns when selecting empirical antibiotic therapy
• Regularly review and adjust treatment based on microbiological findings
• Implement infection control measures in high-risk patient populations

References

• Study on PBSIs in hematologic patients